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± 109) (P = 0.025). Mean nursing home costs amounted to c3243 (±2700) per patient 
during the ﬁ nal month of life. Mean nursing home costs per patient of c3822 (±3232) 
for patients receiving usual care were higher than costs of c2456 (±2117) for patients 
receiving palliative care (P = 0.068). CONCLUSIONS: This study suggests that pallia-
tive care models in acute hospital wards and in nursing homes need to be supported 
because such care models appear to be less expensive than usual care and because 
such care models are likely to better reﬂ ect the needs of terminal patients.
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OBJECTIVES: To measure the efﬁ ciency of pharmacy resources utilization in 13 
Primary Care centres by the retrospective application of Adjusted Clinical Groups (ACG) 
in a usual clinical practice setting. METHODS: Retrospective study carried out on the 
basis of the clinical records from all the attended patients along the year 2008. Main 
variables: age, sex, case-mix/episodes, visits, pharmacy costs, 13 centres, physician and 
service (Family Medicine or Paediatrics). ACG grouper (Starﬁ eld and Weiner, Johns 
Hopkins University, n = 106) classiﬁ es each patient in a unique category of similar 
resource consumption. A Receiver Operating Characteristics (ROC-area under the 
curve) analysis was done to assess the predictive value of the model. The Efﬁ ciency Index 
(EI) was obtained as the quotient between the observed and the expected pharmacy 
costs according to ACG distribution (indirect standardization). The statistical package 
SPSS was used (P < 0.05). RESULTS: A total of 227,235 patients were included. Average 
number of episodes 4.5 ± 3.2 and visits 8.1 ± 8.2; mean age: 44.1 ± 23.7 years; and 
55.6% of males. Intensity of utilization: 77.4%. Costs of drug prescription: c70.6 mil-
lions (47.6% of the total costs). Mean cost was c310.8 ± 681.2. ROC curve analysis 
for episodes: 0.588 (p = 0.001); sensibility: 37.3%, speciﬁ city: 73.1% and intra-class 
correlation coefﬁ cient C: 0.732 (P < 0.001). The EI for each centre was analyzed, P < 
0.0001. Furthermore, differences between family physicians and paediatricians were 
observed (range: 0.55–1.46), P < 0.001. CONCLUSIONS: Results show a wide vari-
ability in the costs of pharmacy within centres and physicians. ACG provide an adjusted 
approximation to efﬁ ciency in pharmacy costs. Efﬁ ciency must not be considered as an 
isolated dimension of quality. The determination of the El could lead to a better knowl-
edge of the prescription proﬁ le from individual physicians and/or primary care teams.
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OBJECTIVES: Economic evaluation has been promoted as a tool to guide decision-
making processes regarding health care resources’ allocation and in the adoption of 
health care technologies. We analyzed the evolution and the main characteristics of 
economic evaluations of health care interventions done during the period 1983–2008 
in Spain. METHODS: Observational descriptive study. We performed a systematic 
review in the main bibliographic databases (PubMed/MEDLINE, SCOPUS, ISI Web of 
Knowledge, CRD, IME, IBECS) and manually through Internet in journals and public 
reports. There were predeﬁ ned inclusion and exclusion criteria, and a set of variables 
to analyze the characteristics of the selected reports. RESULTS: In total, 477 studies 
fulﬁ lled inclusion criteria. Some of the studies characteristics were: cost-effectivenes 
analysis (62.5%), decision analysis techniques (34.0%), heath care system perspective 
(42.1%), therapeutic interventions (70.0%) and non explicit ﬁ nancing (44.0%). The 
geographical distribution for Spanish regions of the ﬁ rst authors was: Catalonia 
(29.3%), Community of Madrid (23.7%), Andalusia (6.7%) and Region of Valencia 
(6.3%). a total of 50.9% of the principal authors were employed at hospital centers. 
The most commontly disease conditions were: cardiovascular diseases (15.7%), infec-
tious and parasitic diseases (15.3%) and malignant neoplasms (13.2%). a total of 82.2% 
of the reports provided recommendations guide for decision making. CONCLUSIONS: 
An increasing number of studies was observed. Identiﬁ ed reports combined heterogene-
ity in the quality of the information brought with regard to analysis methods, data 
sources, type of interventions, or disease conditions. It is suggested to do more efforts 
for improving the quantity and quality of reports in public health interventions.
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OBJECTIVES: The Chronic disease are ones of high prevalence, duration and slow 
progression, its cure could not be predicted clearly or will never be. In general, are 
related to lifestyles and population that is older. To determine the direct sanitary cost 
depending on chronic comorbidity grade (risk) in patients attended in a primary care 
setting (PC). METHODS: Retrospective multicentre design. Patients over 14 years 
were included, pertaining at 6 PC teams that demand assistance during year 2008. 
Main measures: sociodemographics, risk/casuistic/comorbidity, Charlson index (sever-
ity) and direct cost models. The chronic comorbidity was classiﬁ ed beginning from 
Adjusted Clinical Groups. It was obtained the Resources Utilization Bands (RUB) per 
patient (rank: 1- healthy user to 5- high morbidity). The complexity/comorbidity was 
grouped in 10 categories (6 expert forum). Fixed/semi ﬁ xed cost were considered 
(functioning: salary, services, purchases) and variable (tests, referrals, drugs). Explana-
tion power calculation: determination coefﬁ cient (R2). It was made an ANOVA analy-
sis for the correction (age, sex, comorbidity) of the models (procedure: Bonferroni). 
SPSSWIN program; P < 0.05. RESULTS: A total of 69,653 patients, age-average: 47.6 
± 18.8 years; women: 54.1%; high morbidity: 4.8%; chronic disease: 3.8 ± 2.3 and 
total cost: c51.3 million (ﬁ xed cost: 12.3%). The 35.4% (n = 24,670; CI: 34.5–36.3%) 
showed ≥5 chronic disease. Binary correlations: comorbidity-BUR: 0.716; cost-comor-
bidity: 0.596; age-comorbidity: 0.429; P < 0,001. Osseo-muscular illness (38.1%), 
mental (31.6%) and cardiovascular (30.4%) were the same frequencies, P < 0.001. 
The unitary average of the cost corrected was of c736.74 ± c921.97, with comorbidity 
ranks between: 1 = 309.62; 5 = 842.99; 10 = c2,354.05, respectively, P < 0.001. 
Predictive model (R2): age = 25.7%; age-sex = 26.5%; age-sex-comorbidity = 60.3%, 
of the cost. Women showed more comorbidity. CONCLUSIONS: Chronic comorbid-
ity is associated with a sanitary cost increase. The number of comorbidities explains 
the major part of the cost. Patient knowledge of risk/complexity enable us doing dif-
ferent strategies of preventive/cure intervention. KEY WORDS: comorbidity, cost, 
resource use, risk.
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OBJECTIVES: Austria’s health insurance system is divided into 13 sickness funds. 
Each fund has its own fee structure with individual names and codes for every pro-
cedure performed in an outpatient setting. Outpatient setting includes general practi-
tioners, specialists, ambulatories and institutes. Each sickness fund has general 
contracts for GPs and specialists while each institute has its own contract. These 
contracts partly include procedures that are not comparable with any procedures of 
other sickness funds. Some sickness funds pay physicians and institutes different fees 
for same procedures. Moreover, the payment depends on the number of procedures 
performed by a physician or institute within a certain period of time. In order to 
evaluate procedure data, the so called meta-fee-structure, a set of pre-deﬁ ned, stan-
dardized procedures that are mapped by individual fee-structures, was developed. 
METHODS: Given data with frequencies and costs of procedures for every sickness 
fund we are going to propose methods for examining and compare these data: Com-
paring the cumulative costs, frequencies, the average rates for procedures and the rates 
for different institutes and physicians paid by different sickness funds. All methods 
are then applied on real data in the ﬁ eld of radiology. RESULTS: By using this process 
with real world data it is possible to show the potential of these methods, lacks in 
data quality and the limitations of the meta-fee structure. Furthermore it is possible 
to point out proposals where procedure costs should be examined more closely and 
maybe health care costs could be reduced. CONCLUSIONS: Due to the heterogeneous 
health care system of Austria there is a wide variety of issues to be addressed when 
analyzing data. Although the proposed methods are very general they have to be 
adapted to the actual problems. Knowledge about data origin is crucial when choosing 
methods to get high quality results.
PHP51
ROUTINE REPLACEMENT OF PERIPHERAL INTRAVENOUS CATHETER 
VERSUS CLINICALLY INDICATED REPLACEMENT: A COST 
COMPARISON STUDY FROM THE PUBLIC PAYER PERSPECTIVE
Tolentino ACM, Takemoto ML, Fernandes RA, Passos RB, Cukier FN
ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil
OBJECTIVES: IV catheterization is the most common invasive procedure among 
hospitalized patients and the widest practiced to prevent complications is routine 
replacement of the catheter (RCC) in ﬁ xed intervals. a meta-analysis (Webster 2008) 
showed no signiﬁ cant differences in terms of efﬁ cacy from RCC and replacement only 
when clinically indicated (RCI). This study aims to compare costs and consequences 
of RCC versus RCI from the public payer perspective. METHODS: Efﬁ cacy data was 
obtained from Webster 2008 which showed no clinical beneﬁ ts of RCC over RCI. 
Data from the Brazilian Hospital Information System (SIH/DATASUS) from January 
1–December 31, 2009 was used to deﬁ ne the annual number of admissions of adult 
patients in public hospitals wards, assuming RCC as the current practice (no ICU 
patients included). The mean length of stay (LOS) and the mean time to replacement 
(TTR) were used to calculate the number of replacements in each scenario. Resource 
utilization was estimated through published data and unit costs were obtained from 
Brazilian ofﬁ cial price lists. RESULTS: A total of 8,985,758 hospitalizations were 
identiﬁ ed in the database in 2009 with mean LOS of 5.53 days (132.66 hours). 
According to a published randomized clinical trial included in Webster 2008, mean 
TTR for RCC and RCI was 66.5 and 90.6 hours, respectively, resulting in average 
1.99 and 1.46 replacements per hospitalization in each setting. The estimated cost of 
replacement was 2.54BRL (nursing time and medical supplies). For all admissions, the 
total cost for RCC and RCI was 45,556,510BRL and 33,438,277BRL. The estimated 
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savings were 12,118,232BRL/year for the public health care system or 1,348BRL/year 
per 1,000 admissions. CONCLUSIONS: RCI has shown similar efﬁ cacy when com-
pared to RCC with fewer costs. The cost difference was mild in magnitude but when 
extrapolated to a large-scale perspective these results reinforce the need of evidence-
based decision making and rational resource allocation.
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OBJECTIVES: In Germany, the ﬁ nancing mechanism aggravates the cost issue of so 
called high-utilizers. So far, there were no care management concepts as the mostly 
multimorbid, complex medical conditions were judged as individual, non-inﬂ uenceable 
cases. We developed a method to reveal issues in treatment and care of this special 
insurance population to increase efﬁ ciency. METHODS: The most critical challenge for 
insurance companies lies in the identiﬁ cation of relevant insured, in order to speciﬁ cally 
target the high effort of control and management. In this project we analyzed the second-
ary data of the members of a German insurance company in the course of four years. 
Based on this we ﬁ rst differentiated high-utilizers from average-utilizers. In the following 
we deﬂ ected by which means existing care management concepts could be comple-
mented. Based on the longterm data observation we developed a prognostic model to 
predict future high-utilizers. RESULTS: High-utilizers were deﬁ ned as the 5% most 
expensive insurance-members, who generated 50% of total spending. We distinguished 
high-utilizers who caused the main costs in one speciﬁ c care sector (pharmaceuticals and 
hospital) and patients who caused costs in multiple sectors (transsectoral). In addition, 
ultra high-utilizers were considered separately due to their extreme cost provocation. 
While it is possible to manage the ﬁ rst two groups by a combination or extension of 
existing cost reduction measures and care approaches such as disease management 
programs, ultra high-utilizers should be addressed by an individual and speciﬁ cally 
developed case management. CONCLUSIONS: This segment of insured demands a 
stringent, integrated approach in order to efﬁ ciently employ the available ﬁ nancial 
resources. This study aims to explain a practical system for the controlling and manage-
ment of expenses caused by high-utilizers based on our conclusion that the early iden-
tiﬁ cation and the speciﬁ c management of high-utilizers in health care holds high ﬁ nancial 
potential and targeted programs are promising for care optimization.
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OBJECTIVES: The purpose of this study was to determine the unit cost of the main 
production centers of Ankara University Faculty of Medicine Hospitals in 2008. 
METHODS: Expenses and costs of the two hospitals of Ankara University (Ibni Sina 
and Cebeci Hospitals) were obtained from the Hospital Information System and 
Revolving Fund distributed to the main production centers by using a step-down 
allocation method with ﬁ ve allocation steps. Unit costs were calculated in the last step. 
To determine the cost for outpatient and inpatient units, the data from the ﬁ fth alloca-
tion including the number of outpatients and inpatients as well as the number of 
inpatient days was used. RESULTS: The total cost of Ibni Sina Hospital (a 931-bed 
facility) and Cebeci Hospital (a 1153-bed facility) were calculated as c55,137,708.41 
and c49,709,800.84 respectively. In Ibni Sina Hospital, among outpatient units, Dept. 
of Hematology had the highest, while the Aphaeresis Unit had the lowest cost. As to 
the inpatient unit costs, Dept. of Internal Diseases had the highest, and Dept. of Ear, 
Nose and Throat had the lowest cost. In Cebeci Hospital, Dept. of Algology had the 
highest outpatient unit cost, and Consultation-Liaison Psychiatry had the lowest 
outpatient unit cost. In terms of number of inpatients, Dept. of Pediatrics had the 
highest, while the Aphaeresis Unit had the lowest unit cost. Nuclear Medicine Depart-
ment had the highest cost, while the Aphaeresis Unit had the lowest clinic unit cost 
with respect to inpatient hospital days. CONCLUSIONS: The results of this study 
show that the unit costs of outpatient clinics are higher in the departments of internal 
medicine compared to the departments of surgery whereas the reverse is true for 
inpatient clinics. Being aware of unit costs in a large-size hospital would improve 
strategic decision-making process including effective ﬁ nancial management, health 
care service planning and human resources management.
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OBJECTIVES: Budget impact (BI) of orphan drugs (ODs) has increased over the past 
10 years as more ODs entered the market since the introduction of the EU Regulation 
on Orphan Medicinal Products. The aim of this study is to determine the BI of ODs 
in a selection of countries where a large number of authorized ODs are reimbursed. 
METHODS: Public data on OD expenditure in Denmark was collected. The BI was 
calculated per product for the period 2005–2009. Subgroup analyses were performed 
for different types of treatment setting and ATC classes. The results of Denmark were 
compared to data collected for France (total OD costs for 2002–2009 speciﬁ ed per 
treatment setting) and for Belgium (budget estimates per product for 2008). RESULTS: 
Total BI of ODs in Denmark increased from 20.3Mc for 13 reimbursed ODs out of 
22 (59%) authorized ODs in 2005 to c58.3M for 41 out of 60 (68%) authorized ODs 
in 2009. Highest costs were for oncology drugs (57%–67% of total BI in 2005–2009) 
and for metabolism drugs (19%–30% in 2005–2009). Outpatient drugs accounted 
for 0.01% (2005) to 1.55% (2009) of total BI of ODs. In France, 34 ODs were 
reimbursed in 2008 and the BI increased from c71M in 2002 to c496M in 2008. In 
2008, the BI represented 1.8% of the total value of drugs sold. The situation in 
Belgium is comparable as the total BI of ODs was c66.2M in 2008 representing 2% 
of total reimbursed drug costs. CONCLUSIONS: Although cost per patient is rela-
tively high, total BI for a country is still modest as a result of lower volumes used. 
The results show a consistent picture for OD expenditure across different health care 
systems. Budget restrictions are not widely used for ODs but this might change when 
the anticipated increase in BI of ODs becomes more apparent.
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INNOVATIVE PERFORMANCE IN EUROPE
Trevor NC, Tang M, Samuels ER
Heron Evidence Development Ltd, London, UK
OBJECTIVES: At the 2000 Lisbon Summit, the European Council set the quantitative 
target to increase R&D investment in all EU countries to 3% GDP by 2010. Today, 
there is growing emphasis on innovation in R&D, particularly in the development of 
pharmaceuticals, with the European Innovation Scoreboard (EIS) publishing annual 
ranking of the 27 EU member states to track and benchmark innovation performance. 
This work aims to explore the potential relationship between R&D investment and EIS 
innovation performance. In addition, the impact of national or regional innovation 
plans/policy will be considered. METHODS: The EIS innovation performance results 
for 2009 (based on data from 2005) were identiﬁ ed as the primary measure of innova-
tion performance. The EIS includes 7 dimensions to accommodate the diversity of 
innovation processes and models that occur in varying national contexts. Eurostat data 
were used to identify the R&D investment in 2005. In order to identify the importance 
of R&D investment (%GDP) to EIS position, a simple quantitative linear regression was 
conducted. Supplementary qualitative literature searches were conducted to identify 
national and regional innovation plans and policies. RESULTS: The simple linear regres-
sion revealed a signiﬁ cant (P < 0.00005) relationship between R&D investment and 
position within the EIS innovation performance, with R&D investment explaining 72% 
of the scoreboard results. However, other dimensions have a noteworthy effect on 
innovation performance, since although the UK was identiﬁ ed as an innovation leader 
(along with Denmark, Finland, Germany, and Sweden), the UK ranks only 8th in terms 
of %GDP R&D investment. In this case, the presence of a national plan for innovation, 
alongside other factors, has led to high innovative performance. CONCLUSIONS: 
Although R&D has a signiﬁ cant effect on innovation performance, other dimensions 
also have a noteworthy effect. For example, the presence of national plans for innovation 
may aid a country in gaining innovation leader status.
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OBJECTIVES: The primary aim was to determine the extent of provision of Pharma-
cist Initiated Therapy (PIT) services in pharmacies in South Africa and the time it takes 
to provide this service. METHODS: A national research project was undertaken 
during 2008 by the South African Pharmacy Council on the services for which a 
pharmacist may levy a fee. The focus of this study is on one component of the larger 
study, namely the PIT service. RESULTS: A total of 369 pharmacies provided PIT 
services, and 3133 PIT services (cases) were measured. The majority were delivered 
by community (retail) pharmacies (95.79%). The PIT service was divided into three 
phases: Phase I (pre-administration procedure), Phase II (preparation and labelling of 
the prescribed medicine) and Phase III (provision of information and instructions to 
the patient to ensure the safe and effective use of medicine). Phase I was performed 
in 98.21% of cases, Phase II in 97.19% of cases and Phase III in 91.67% of cases. 
Pharmacists mostly delivered all three phases themselves (over 70% of cases). The 
weighted average time it took for a PIT service to be delivered was 199.02 seconds 
(just under 3.5 minutes) (SEM = 5.57 seconds). The weighted average time in com-
munity pharmacies was slightly less (192.82 seconds) compared to 312.15 seconds in 
private institutional pharmacies. The time taken was dependent on the number of 
items dispensed. The weighted average time taken was 160.76 seconds if there was 1 
item dispensed, 220.31 seconds for more than 1 and equal to 2 items dispensed, and 
327.19 seconds if more than 2 items were dispensed. a pharmacist may currently 
